An Association between Carpal Tunnel Syndrome and Migraine Headaches—National Health Interview Survey, 2010

Huay-Zong Law, MD
Bardia Amirlak, MD
Jonathan Cheng, MD
Douglas M. Sammer, MD

**Background:** Migraine headaches have not historically been considered a compression neuropathy. Recent studies suggest that some migraines are successfully treated by targeted peripheral nerve decompression. Other compression neuropathies have previously been associated with one another. The goal of this study is to evaluate whether an association exists between migraines and carpal tunnel syndrome (CTS), the most common compression neuropathy.

**Methods:** Data from 25,880 respondents of the cross-sectional 2010 National Health Interview Survey were used to calculate nationally representative prevalence estimates and 95% confidence intervals (95% CIs) of CTS and migraine headaches. Logistic regression was used to calculate adjusted odds ratios (aORs) and 95% CI for the degree of association between migraines and CTS after controlling for known demographic and health-related factors.

**Results:** CTS was associated with older age, female gender, obesity, diabetes, and smoking. CTS was less common in Hispanics and Asians. Migraine was associated with younger age, female gender, obesity, diabetes, and current smoking. Migraine was less common in Asians. Migraine prevalence was 34% in those with CTS compared with 16% in those without CTS (aOR, 2.60; 95% CI, 2.16–3.13). CTS prevalence in patients with migraine headache was 8% compared with 3% in those without migraine headache (aOR, 2.67; 95% CI, 2.22–3.22).

**Conclusions:** This study is the first to demonstrate an association between CTS and migraine headache. Longitudinal and genetic studies with physician verification of migraine headaches and CTS are needed to further define this association. (Plast Reconstr Surg Glob Open 2015;3:e333; doi: 10.1097/GOX.0000000000000257; Published online 19 March 2015.)

Carpal tunnel syndrome and migraine headache are common disorders, affecting up to 6%–5 and 15%–12 of the adult population, respectively. Both result in substantial burden to patients and society. Migraine headaches cause 112 million bedridden days per year13–14 and generate annual costs totaling up to 17 billion dollars in the United States alone.14,15 In spite of the high prevalence and socioeconomic burden imposed by carpal tunnel syndrome and migraine headache, the precise etiology of both conditions remains poorly understood.

Carpal tunnel syndrome is the most common disorder in a larger family of compression neuropathies, which includes cubital tunnel syndrome, peroneal neuropathy, tarsal tunnel syndrome, ra-

**Disclosure:** The authors have no financial interest to declare in relation to the content of this article. The Article Processing Charge was paid for by the authors.

From the Department of Plastic Surgery, University of Texas Southwestern Medical Center at Dallas, Dallas, Tex.
Received for publication February 20, 2014; accepted November 13, 2014.
Copyright © 2015 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
DOI: 10.1097/GOX.0000000000000257

www.PRSGlobalOpen.com
dial tunnel syndrome, pronator syndrome, thoracic outlet syndrome, and others. Several studies in the literature support an epidemiologic association between different compression neuropathies such as cubital tunnel syndrome and carpal tunnel syndrome and thoracic outlet syndrome and carpal tunnel syndrome. The cause of these associations is poorly understood and may be multifactorial.

Migraine headache, on the other hand, has not historically been considered to be a compression neuropathy. Recently, however, there is some evidence that migraine headache may be triggered by nerve compression in the head and neck, with some patients responding to nerve decompression by surgical release. In addition, the effects of botulinum toxin, either by direct action on the nerve or by weakening of the overlying muscle, may point further to this theory. The purpose of this study is to evaluate the hypothesis that an association exists between carpal tunnel syndrome and migraine headache.

MATERIALS AND METHODS

Data from the Adult Core module of the 2010 National Health Interview Survey (NHIS) were used to calculate prevalence estimates for carpal tunnel syndrome and migraine headache. The NHIS is an annual, in-person health survey of the civilian, non-institutionalized population of the United States. The survey is administered throughout the year. Analyses were restricted to adults that provided complete information for carpal tunnel syndrome status, migraine headache status, and covariates as listed below. Race/ethnicity groups were excluded if unable to be included in the logistic regression analysis due to too few respondents. All estimates were calculated using provided final sample weights to produce nationally representative estimates that adjust for the stratified sampling design of the survey.

A case of carpal tunnel syndrome was defined as a respondent who answered “yes” to both questions, “Have you ever been told by a doctor or other health professional that you have a condition affecting the wrist and hand called carpal tunnel syndrome?” and “During the past 12 months have you had carpal tunnel syndrome?” A case of migraine headache was defined as a respondent who answered “yes” to the question, “During the past 3 months, did you have migraine headache?” Demographic covariates included age (18–34, 35–49, 50–64, and ≥65 years); gender; and race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, and Asian). Health status and behavior covariates included body mass index (BMI) (≤24.99 = healthy or underweight, 25.00–29.99 = overweight, and ≥30.00 = obese); diabetes status (yes/no); and smoking status (current, former, and never). These covariates have all previously been associated with these conditions and were available in this database. These age groups were selected to provide similar ranges of age (15- to 17-year range in youngest 3 groups) and to ensure sufficient responses in each group to allow for reliable reporting of statistics. The BMI categories are based on categories defined by the Centers for Disease Control and Prevention.

Statistical Analysis

All analyses were performed with SAS software, version 9.3 (SAS Institute, Cary, N.C.). All respondents—including those with missing data—remained in the analysis universe to maintain accurate variance estimates, with domain analyses performed for those records with and without missing variable data. Given the stratified sampling design, the SURVEYFREQ function was used to determine weighted distribution and prevalence rates with 95% confidence intervals (CIs) by each covariate for both carpal tunnel syndrome and migraine headache. Chi-square analyses were used to determine statistically significant differences among subgroups. All covariates were found to be significant (P < 0.05) in bivariate analyses and were included in the multivariate regression models. The multivariate logistic regression models were used to control for confounding by covariates. Given the sampling design, the SURVEYLOGISTIC function was used to calculate weighted adjusted odds ratios (aORs) with 95% CI for having carpal tunnel syndrome and for having migraine headache. Collinearity was evaluated by calculating variance inflation factors (VIFs) for each covariate. All VIFs were less than 2, below the common convention criterion of VIF < 10.

RESULTS

Of the 27,157 respondents who completed the Sample Adult module of the survey, 1277 (4.7%) were excluded due to incomplete data or insufficient respondents within a race/ethnicity group. The final analysis was based on 25,880 respondents, of which 952 (3.7%) had carpal tunnel syndrome and 4212 (16.3%) had migraine headache as defined above. Table 1 displays the weighted distribution of those with carpal tunnel syndrome and those with migraine headache by demographic and health characteristics.

Table 2 demonstrates the weighted prevalence with 95% CI and aOR for having carpal tunnel syndrome or migraine headache by these demographic and health characteristics, with bold figures denoting statistical significance. In terms of demographics,
the prevalence of carpal tunnel syndrome increased with age, peaking in the 49- to 64-year-old group. On the other hand, prevalence of migraine headache generally decreased with age. Female gender was associated with both carpal tunnel syndrome and migraine headache. Carpal tunnel syndrome was less prevalent among Hispanics and Asians compared to the reference group (non-Hispanic White), and migraine headache was less prevalent among Asians compared to the reference group (non-Hispanic White). In terms of health status and behavior variables, increased BMI was associated with both carpal tunnel syndrome and migraine headache, as was diabetes mellitus. Both current smoker status and former smoker status were associated with an increased odds of carpal tunnel syndrome, whereas only current smoker status was associated with an increased odds of migraine headache.

Table 3 demonstrates the weighted prevalence and aOR of having carpal tunnel syndrome or migraine headache in the presence or absence of the other condition. A significant positive correlation was found after adjusting for demographic and health/behavior variables. The prevalence of migraine headache was 8% compared with 3% in those without migraine headache (aOR, 2.67).

**DISCUSSION**

The current study is the first to demonstrate an association between carpal tunnel syndrome and migraine headache. Carpal tunnel syndrome is the most common disease process within the larger family of compression neuropathies. Migraine headache, on the other hand, has not historically been considered to be a compression neuropathy. Although some authors previously proposed an extracranial component to migraine pathogenesis,42,43 further recent evidence supports that some migraine headaches may be associated with nerve compression within the head and neck.28–30,34,44 This concept remains controversial and is debated heavily within the medical community.45 Of note, a recent survey of members of the American Headache Society reported that nerve blocks and trigger point injections are commonly used by its members to treat migraine headache,46 and several other studies support targeted injections of botulinum toxin or local anesthetic for the treatment of migraine headaches.33–38,47–49
false-positive respondents without true migraine headaches. Respondents with other types of headaches such as occipital neuralgia, new daily persistent headaches, cluster headaches, and others could have been included. However, the migraine prevalence in the current study, both in terms of overall prevalence (16.3%) and prevalence by age group and gender, is consistent with previously published migraine-specific studies. In a 2006 study of 145,335 participants, the prevalence of migraine headache in the adult population using the International Classification of Headache Disorders (ICHD) criteria was found to be 15%. In our study, there was additional concordance with the published literature on migraine epidemiology with the positive correlations seen between migraine and risk factors such as obesity and smoking. Finally, it should be noted that numerous other studies have used the same database (NHIS) to study migraine headache, providing precedent for the use of this database in our current study. However, even though the migraine headache overall prevalence and subgroup prevalence found in this study are consistent with the existing literature, and the NHIS database has previously been used for studying migraine headache, the wording of the survey remains an important limitation. The results of this study should be interpreted within this limited context.

**Table 2. Weighted Prevalence and Adjusted Odds Ratio of Carpal Tunnel Syndrome or Migraine Headache by General and Health Characteristics, National Health Interview Survey 2010**

| Demographic Category | Carpal Tunnel Syndrome (N = 952) | Migraine Headache (N = 4212) |
|----------------------|----------------------------------|------------------------------|
|                      | Weighted % (95% CI) | aOR (95% CI) | Weighted % (95% CI) | aOR (95% CI) |
| **General**          |                    |                |                        |               |
| Age group (years)    |                    |                |                        |               |
| 18–34                | 1.2 (0.9–1.5)      | Reference      | 19.9 (18.8–21.1)      | Reference     |
| 35–49                | 4.1 (3.5–4.6)      | 3.05 (2.28–4.09) | 20.1 (18.9–21.3)      | 0.92 (0.85–1.02) |
| 49–64                | 5.8 (5.0–6.6)      | 4.33 (3.21–5.85) | 14.4 (13.4–15.4)      | 0.57 (0.51–0.65) |
| ≥ 65                 | 3.8 (3.2–4.4)      | 3.11 (2.21–4.39) | 6.3 (5.5–7.1)         | 0.23 (0.19–0.27) |
| **Gender**           |                    |                |                        |               |
| Male                 | 2.4 (2.1–2.8)      | Reference      | 11.0 (10.3–11.7)      | Reference     |
| Female               | 4.7 (4.3–5.1)      | 1.93 (1.60–2.31) | 21.5 (20.6–22.3)      | 2.40 (2.18–2.65) |
| **Race/ethnicity**   |                    |                |                        |               |
| Non-Hispanic White   | 3.8 (3.5–4.2)      | Reference      | 16.1 (15.5–16.8)      | Reference     |
| Non-Hispanic Black   | 4.2 (3.4–5.0)      | 1.02 (0.82–1.26) | 18.9 (17.5–20.3)      | 1.05 (0.92–1.14) |
| Hispanic             | 2.5 (2.0–3.0)      | 0.72 (0.56–0.92) | 16.8 (15.6–18.1)      | 0.95 (0.85–1.05) |
| Asian                | 1.5 (0.7–2.2)      | 0.52 (0.31–0.88) | 10.3 (8.4–12.2)       | 0.61 (0.49–0.75) |
| **Health status and behaviors** | | | | |
| Body mass index      |                    |                |                        |               |
| Normal or underweight| 2.3 (2.0–2.6)      | Reference      | 15.8 (14.8–16.7)      | Reference     |
| Overweight           | 3.4 (3.0–3.9)      | 1.50 (1.24–1.80) | 14.6 (13.8–15.5)      | 1.11 (1.00–1.25) |
| Obese                | 5.5 (4.9–6.1)      | 2.01 (1.65–2.45) | 19.1 (18.0–20.2)      | 1.35 (1.19–1.49) |
| Diabetes mellitus    |                    |                |                        |               |
| Yes                  | 7.1 (5.9–8.3)      | 1.59 (1.27–1.98) | 16.0 (14.4–17.7)      | 1.32 (1.15–1.55) |
| No                   | 3.2 (2.9–3.5)      | Reference      | 16.3 (15.7–16.9)      | Reference     |
| Smoking status       |                    |                |                        |               |
| Current smoker       | 4.8 (4.1–5.5)      | 1.64 (1.35–1.98) | 22.1 (20.7–23.4)      | 1.57 (1.41–1.74) |
| Former smoker        | 4.4 (3.7–5.0)      | 1.29 (1.06–1.59) | 13.0 (12.0–14.0)      | 1.06 (0.95–1.19) |
| Never smoked         | 2.9 (2.6–3.2)      | Reference      | 15.6 (14.9–16.4)      | Reference     |
| Overall              | 3.6 (3.3–3.9)      |                | 16.3 (15.8–16.8)      |               |

Bold values indicate statistical significance.

**Table 3. Weighted Prevalence and Adjusted Odds Ratio of Carpal Tunnel Syndrome or Migraine Headache in the Presence or Absence of the Other Condition, National Health Interview Survey 2010**

| Carpal tunnel syndrome (N = 952) | Migraine Headache (N = 4212) |
|----------------------------------|------------------------------|
| Weighted % (95% CI) | aOR (95% CI) | Weighted % (95% CI) | aOR (95% CI) |
| Yes                             | 7.6 (6.6–8.5) | **2.67** (2.22–3.22) | 34.4 (30.7–38.1) | **2.60** (2.16–3.13) |
| No                              | 2.8 (2.6–3.1) | Reference            | 15.6 (15.1–16.2) | Reference            |

Bold values indicate statistical significance.
Another limitation is the fact that this was a survey-based study and did not consist of patients with carpal tunnel syndrome or migraine headache diagnoses confirmed by a medical professional. The survey questions rely upon the respondents’ understanding of their own health status. Respondents with mild or early symptoms may not have been aware of their disease process, such as can occur with carpal tunnel syndrome. This may have led to underreporting or resulted in a bias toward more severe manifestations of disease. Also, because of the survey design, noncivilian and institutionalized persons were not accounted for, which could skew the results. Smaller ethnic groups such as Native American Indian and Alaskan Native were unable to be separately analyzed due to an insufficient number of respondents. Socioeconomic data, such as income, are missing for a large number of records and could not be incorporated into the model. Other studies have demonstrated a higher prevalence of migraine headache among households in lower income groups.6,7,62

Another limitation is that carpal tunnel syndrome and migraine headache are treatable conditions, so the wording of the survey questions (eg, “within the last 12 months”) likely resulted in negative respondents who may have had either disease process in the past. Furthermore, because carpal tunnel syndrome and migraine headache have different age distributions, with migraine headache more prevalent in younger age groups and carpal tunnel prevalence increasing with age, the wording of the questions may underestimate the true strength of the association. For example, the association would be missed for a person who had migraine headaches that resolved at a younger age, followed by the development of carpal tunnel syndrome at an older age. The association may have been stronger had it been possible to identify patients who had ever had migraine headache.

One of the strengths of the current study is that the NHIS is designed to be nationally representative, adding to the generalizability of our study.49 Also, the survey design allows for inclusion of underrepresented age groups and ethnicities such as the elderly, Asian, Hispanic, and non-Hispanic Black populations. This can be especially useful for identifying populations at significantly higher or lower risk, providing clues about etiology. This study is also consistent with previously identified risk factors as above for both carpal tunnel syndrome and migraine headache, supporting the validity of the analysis. Furthermore, these risk factors were adjusted for in the statistical analysis, making the aOR a more realistic indicator of association.

Similar to other peripheral neuropathies such as carpal tunnel syndrome, the precise pathophysiology of migraine headache remains unclear. The underlying cause connecting seemingly unrelated compression neuropathies such as carpal tunnel syndrome and cubital tunnel syndrome,20,21 and between carpal tunnel syndrome and thoracic outlet syndrome,25,26 currently remains unknown. The contributing factors may include a common associated comorbidity11,58,65–67 or a common genetic factor68,69 leading to increased susceptibility to compression within the peripheral nervous system. In 1988, Del-lon et al70 demonstrated in an animal model that the nerves of animals with diabetes are more susceptible to compression than the nerves of animals without diabetes. However, diabetes was adjusted for within the current study, making this an unlikely cause for the association between migraine headache and carpal tunnel syndrome. Furthermore, although diabetes is a well-defined risk factor for carpal tunnel syndrome,4,63,64 the association between diabetes and migraine headache is less clear in the literature.5,60,66

Multiple compression neuropathies have also been noted in other situations. The “double-crush” phenomenon is well described and occurs when compression of a nerve at one location impedes axonal flow, making the nerve more susceptible to compression at another location.25,71 Although this may explain some cases of associated compression neuropathies within the same nerve tract, it does not explain associated compression neuropathies that occur within anatomically distinct peripheral nerves and would not explain the association between carpal tunnel syndrome and migraine headache.

Hereditary neuropathy with liability to pressure palsies (HNPP) is an uncommon condition that results in recurrent focal compression neuropathies, primarily of the median, ulnar, and peroneal nerves.68,69 Hereditary neuropathy with liability to pressure palsies is an autosomal dominant disease and has been attributed to a defect in chromosome 17 that results in abnormal myelin protein 22.72,73 Although this rare disease does not account for the association between carpal tunnel syndrome and migraine headache, it does demonstrate that an underlying genetic abnormality can result in susceptibility to nerve compression throughout the entire peripheral nervous system.

There is increasing recognition of a central nervous system component to peripheral neuropathies.74–76 Similarly, our understanding of migraine headaches is growing to incorporate peripheral nervous system contributions to what is often considered a purely central pathology. We are not proposing that migraines are purely peripheral phenomena, though, especially because some migraineurs who are pain-free after sur-
gical release continue to experience auras.\textsuperscript{31} An alternative explanation is that peripheral compression or irritation leads to central sensitization which increases the likelihood of suffering from future peripheral neuropathy in other areas.\textsuperscript{77} Because migraine headache is more common in younger patients, and carpal tunnel syndrome is more prevalent in older patients, migraine headache could conceivably sensitize the central nervous system to develop pain from later nerve compression in the carpal tunnel.

Based on the findings of this study and prior studies, it may be worthwhile in patients with migraine to perform an examination for peripheral nerve compression in the head and neck. Potential compression points include the supraorbital and supratrochlear,\textsuperscript{27,29,48,88} auriculotemporal,\textsuperscript{29,81,82} zygomaticotemporal,\textsuperscript{85,84} greater occipital,\textsuperscript{44,47,48,85} third occipital,\textsuperscript{86,87} and lesser occipital\textsuperscript{48,86,88} nerves. Accurate clinical assessment of the origin of any peripheral pain based on history and physical examination of these surface landmarks may broaden our knowledge of the relative contribution of these nerves to migraine symptoms.

Further research is warranted to determine the value of migraine headache as an early indicator of patients who are more likely to develop carpal tunnel syndrome in the future. Identification of migraine headache as a predictor of future carpal tunnel syndrome would allow for earlier diagnosis and treatment, or even prevention, of carpal tunnel syndrome by modification of risk factors. Further research also needs to be performed to evaluate predisposing and genetic factors in those with higher prevalence, protective factors in those with lower prevalence, and the efficacy of interventions to prevent the development of these diseases.

**CONCLUSIONS**

In conclusion, this study demonstrates an association between carpal tunnel syndrome and migraine headache, independent of numerous risk factors and comorbidities. This association suggests the possibility, although not demonstrated in this study, of a common systemic or neurologic risk factor. In addition, migraine headache may be an early warning sign of an increased risk of future carpal tunnel syndrome. Further studies—including genetic and longitudinal studies with physician verification of diagnoses—are needed to further define the relationship between carpal tunnel and migraine headache.

**REFERENCES**

1. Tanaka S, Wild DK, Seligman PJ, et al. The US prevalence of self-reported carpal tunnel syndrome: 1988 National Health Interview Survey data. *Am J Public Health* 1994;84:1846–1848.
2. Blanc PD, Faucett J, Kennedy J, et al. Self-reported carpal tunnel syndrome: predictors of work disability from the National Health Interview Survey Occupational Health Supplement. *Am J Ind Med* 1996;30:362–368.
3. Atroschi I, Gummesson C, Johnson R, et al. Prevalence of carpal tunnel syndrome in a general population. *JAMA* 1999;282:153–158.
4. Perkins BA, Olalaye D, Bril V. Carpal tunnel syndrome in patients with diabetic polyneuropathy. *Diabetes Care* 2002;25:565–569.
5. Luckhaupt SE, Dahlhamer JM, Ward BW, et al. Prevalence and work-relatedness of carpal tunnel syndrome in the working population, United States, 2010 National Health Interview Survey. *Am J Ind Med* 2013;56:615–624.
6. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. *JAMA* 1992;267:64–69.
7. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. *Headache* 2001;41:646–657.
8. Lipton RB, Bigal ME. The epidemiology of migraine. *Am J Med* 2005;118(Suppl 1):35–108.
9. Bigal ME, Liberman JN, Lipton RB. Age-dependent prevalence and clinical features of migraine. *Neurology* 2006;67:246–251.
10. Lipton RB, Bigal ME, Diamond M, et al; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. *Neurology* 2007;68:343–349.
11. Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. *Lancet Neurol* 2008;7:354–361.
12. Smitherman TA, Burch R, Sheikh H, et al. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. *Headache* 2013;53:427–436.
13. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. *Headache* 1993;33:29–35.
14. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. *Arch Intern Med* 1999;159:813–818.
15. Goldberg LD. The cost of migraine and its treatment. *Am J Manag Care* 2005;11(2 Suppl):S62–S67.
16. Palmer DH, Hanrahan LP. Social and economic costs of carpal tunnel surgery. *Instr Course Lect* 1995;44:167–172.
17. Bickel KD. Carpal tunnel syndrome. *J Hand Surg Am* 2010;35:147–152.
18. Arnold WD, Ehbeikh BH. Entrapment neuropathies. *Neural Clin* 2013;31:405–424.
19. Campbell WW, Landau ME. Controversial entrapment neuropathies. *Neurosurg Clin N Am* 2008;19:597–608, vi–vii.
20. Wise DM. Treatment of cubital tunnel syndrome without electrodiagnosis and relationship to multiple crush syndrome. *Plast Reconstr Surg* 2000;105:1241–1243.
21. Russ L, O’Connor SC, Cho KH, et al. Carpal tunnel syndrome and cubital tunnel syndrome: work-related musculoskeletal disorders in four symptomatic radiologists. *AJR Am J Roentgenol* 2003;181:37–42.
22. Seror P, Nathan PA. Relative frequency of nerve conduction abnormalities at carpal tunnel and cubital tunnel in France and the United States: importance of silent neu-
rathropathies and role of ulnar neuropathy after unsuccessful carpal tunnel syndrome release. *Ann Chir Main Mem Supr.*, 1993;12:281–285.

23. Wise DM. Combined median and ulnar entrapment neuropathies. *Plast Reconstr Surg.* 1999;103:2091–2092.

24. Borman H, Kostakoglu N. Combined median and ulnar entrapment neuropathies. *Plast Reconstr Surg.* 1998;102:1780–1781.

25. Novak CB, Mackinnon SE, Patterson GA. Evaluation of patients with thoracic outlet syndrome. *J Hand Surg Am.* 1993;18:299–292.

26. Vaught MS, Brismee JM, Dedrick GS, et al. Association of disturbances in the thoracic outlet in subjects with carpal tunnel syndrome: a case-control study. *J Hand Ther.* 2011;24:44–51; quiz 52.

27. Guyuron B, Varghai A, Michelow BJ, et al. Corrugator supercilii muscle resection and migraine headaches. *Plast Reconstr Surg.* 2000;106:429–434; discussion 435–437.

28. Guyuron B, Kriegler JS, Davis J, et al. Comprehensive surgical treatment of migraine headaches. *Plast Reconstr Surg.* 2005;115:1–9.

29. Guyuron B, Kriegler JS, Davis J, et al. Five-year outcome of surgical treatment of migraine headaches. *Plast Reconstr Surg.* 2011;127:603–608.

30. Kung TA, Guyuron B, Cederna PS. Migraine surgery: a plastic surgery solution for refractory migraine headache. *Plast Reconstr Surg.* 2011;127:181–189.

31. Janis JE, Dhanik A, Howard JH. Validation of the peripheral trigger point theory of migraine headaches: single-surgeon experience using botulinum toxin and surgical decompression. *Plast Reconstr Surg.* 2011;128:123–131.

32. Faber C, Garcia RM, Davis J, et al. A socioeconomic analysis of surgical treatment of migraine headaches. *Plast Reconstr Surg.* 2012;129:871–877.

33. Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. *Headache* 2000;40:445–450.

34. Dodick DW, Turkel CC, DeGryse RE, et al.; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. *Headache* 2010;50:921–936.

35. Aurora SK, Dodick DW, Turkel CC, et al.; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. *Cephalalgia* 2010;30:793–803.

36. Diener HC, Dodick DW, Aurora SK, et al.; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. *Cephalalgia* 2010;30:804–814.

37. Cady RK, Schreiber CP, Porter JA, et al. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. *Headache* 2011;51:21–32.

38. Oteroño A, Ramón C, Pascual J. Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks. *J Headache Pain* 2011;12:235–238.

39. Statistics NCiH. *Data File Documentation, National Health Interview Survey*, 2010 (Machine Readable Data File and Documentation). Hyattsville, Md.: National Center for Health Statistics, Centers for Disease Control and Prevention; 2011.

40. Prevention CDCa. Defining Overweight and Obesity. 2012. Available at: http://www.cdc.gov/obesity/adult/defining.html. Accessed February 1, 2014.

41. O’Brien RM. A caution regarding rules of thumb for variance inflation factors. *Qual Quant.* 2007;41:673–690.

42. Blau JN, Dexter SL. The site of pain origin during migraine attacks. *Cephalalgia* 1981;1:143–147.

43. Gianchetti C, Gianchetti ME, Pisano T, et al. Treatment of migraine attacks by compression of temporal superficial arteries using a device. *Med Sci Monit.* 2009;15:CR185–CR188.

44. Janis JE, Hafte DA, Reece EM, et al. Neurovascular compression of the greater occipital nerve: implications for migraine headaches. *Plast Reconstr Surg.* 2010;126:1996–2001.

45. Shapiro RE. How do migraine attacks stop? *Headache* 2012;52:191–192.

46. Blumenfeld A, Ashkenazi A, Grosberg B, et al. Patterns of use of peripheral nerve blocks and trigger point injections among headache practitioners in the USA: results of the American Headache Society Interventional Procedure Survey (AHS-IPS). *Headache* 2010;50:937–942.

47. Afridi SK, Shields KG, Bhola R, et al. Greater occipital nerve injection in primary headache syndromes: prolonged effects from a single injection. *Pain* 2006;122:126–129.

48. Blumenfeld A, Ashkenazi A, Naphchan U, et al. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches—a narrative review. *Headache* 2013;53:437–446.

49. Becker D, Amirkab B. Beyond beauty: Onobotulinumtoxin A (BOTOX®) and the management of migraine headaches. *Anesth Pain Med.* 2012;2:5–11.

50. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. *Cephalalgia* 1988;8(Suppl 7):1–96.

51. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. *Cephalalgia* 2004;24(Suppl 1):1–600.

52. Silberstein S, Loder E, Diamond S, et al; AMPP Advisory Group. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study. *Cephalalgia* 2007;27:220–229.

53. Bigal ME, Liberman JN, Lipton RB. Obesity and migraine: a population study. *Neurology* 2006;66:545–550.

54. Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. *Neurology* 2006;67:252–257.

55. Keith SW, Wang C, Fontaine KR, et al. BMI and headache classifications for migraine headaches. *Plast Reconstr Surg.* 1999;103:2091–2092.

56. Blumenfeld A, Ashkenazi A, Grosberg B, et al. Patterns of use of peripheral nerve blocks and trigger point injections among headache practitioners in the USA: results of the American Headache Society Interventional Procedure Survey (AHS-IPS). *Headache* 2010;50:937–942.

57. Afridi SK, Shields KG, Bhola R, et al. Greater occipital nerve injection in primary headache syndromes: prolonged effects from a single injection. *Pain* 2006;122:126–129.

58. Blumenfeld A, Ashkenazi A, Naphchan U, et al. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches—a narrative review. *Headache* 2013;53:437–446.

59. Becker D, Amirkab B. Beyond beauty: Onobotulinumtoxin A (BOTOX®) and the management of migraine headaches. *Anesth Pain Med.* 2012;2:5–11.

60. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. *Cephalalgia* 1988;8(Suppl 7):1–96.

61. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. *Cephalalgia* 2004;24(Suppl 1):1–600.

62. Silberstein S, Loder E, Diamond S, et al; AMPP Advisory Group. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study. *Cephalalgia* 2007;27:220–229.

63. Bigal ME, Liberman JN, Lipton RB. Obesity and migraine: a population study. *Neurology* 2006;66:545–550.

64. Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. *Neurology* 2006;67:252–257.

65. Keith SW, Wang C, Fontaine KR, et al. BMI and headache among women: results from 11 epidemiologic datasets. *Obesity (Silver Spring)* 2008;16:377–383.

66. Peterlin BL, Rosso AL, Williams MA, et al. Episodic migraine and obesity and the influence of age, race, and sex. *Neurology* 2013;81:1314–1321.

67. López-Mesonero L, Márquez S, Parra P, et al. Smoking as a precipitating factor for migraine: a survey in medical students. *J Headache Pain* 2009;10:101–103.

68. Sarker MA, Rahman M, Harun-Or-Rashid M, et al. Association of smoked and smokeless tobacco use with migraine: a hospital-based case-control study in Dhaka, Bangladesh. *Jok Indus Dis.* 2013;11:15.

69. Centers for Disease Control. Prevalence of chronic migraine headaches—United States, 1980–1989. *MMWR Morb Mortal Wkly Rep.* 1991;40:331, 337–338.
